Cargando…
Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
Camostat mesilate is in widespread clinical use mainly to treat chronic pancreatitis, and drug-induced lung injury has not been previously reported. However, pulmonary infiltration with peripheral blood eosinophilia appeared after taking camostat mesilate for ten days. The histological findings show...
Autores principales: | Ota, Shinichiro, Hara, Yu, Kanoh, Soichiro, Shinoda, Masahiro, Kawano, Shuichi, Fujikura, Yuji, Kawana, Akihiko, Shinkai, Masaharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925915/ https://www.ncbi.nlm.nih.gov/pubmed/27408783 http://dx.doi.org/10.1016/j.rmcr.2016.06.005 |
Ejemplares similares
-
Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020) -
Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease
por: Hara, Yu, et al.
Publicado: (2017) -
Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
por: Kinoshita, Taku, et al.
Publicado: (2022) -
A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)
por: Kinoshita, Taku, et al.
Publicado: (2022) -
Clinico-pathological analysis referring hemeoxygenase-1 in acute fibrinous and organizing pneumonia patients
por: Hara, Yu, et al.
Publicado: (2015)